Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Theralase® Research - One of the Top 10 Most Downloaded Pape

<< Previous

Bullboard Posts

Next >>

Comment by made2laston Jun 24, 2022 7:51am

310 Views

Post# 34779558

RE:RE:Theralase® Research - One of the Top 10 Most Downloaded Pape

Hi wildbird1;

Happy for an unexpected NR positive beginning on a Friday. Normally they offer a NR on a Monday or Tuesday.

The best to you;

made2last

wildbird1 wrote:
made2last.
You beat me to it.
Definitively very positive.
Sooner or later something very positive is going to happen with TLT.

made2last wrote:
Hi All;

Very positive statement by our Interim CEO

Dr. Arkady Mandel M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer of Theralase® stated, “This is another milestone of excellence achieved by Theralase®. These pre-clinical results led a logical progression to our successfully completed Phase Ib NMIBC clinical study, which demonstrated the safety, pharmacokinetics and efficacy in a first in-human clinical study.

The success in the Phase Ib NMIBC clinical study has led to the impressive preliminary results demonstrated in the Phase II NMIBC clinical study, focused primarily on efficacy and secondarily on safety. In the future, I foresee great potential for Theralase® Anti-Cancer Therapy (“ ACT ”) to deliver a safe and effective anti-cancer treatment for numerous cancer indications with high unmet needs."

Thanks;

made2last